Research from a collaborative team of biomedical engineers, physicians and scientists could enable significant advances for the 40,000 pediatric congenital heart disease patients (CHD) born each year.
A chemotherapy drug used to fight bone-marrow cancer also has the potential to treat and prevent potentially deadly heart failure, a powerful new drug-screening tool developed at UVA Health suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback